Experimental Anxiety Medication MM120 Shows Effects Lasting 12 Weeks in Phase 2b Trial
A Phase 2b clinical trial of MM120, a pharmaceutical-grade form of lysergide being developed as an anxiety treatment, found significant reductions in anxiety symptoms that lasted at least 12 weeks after dosing, with response rates substantially exceeding placebo.
What the Trial Found
Participants with generalized anxiety disorder who received MM120 showed significant improvement in anxiety symptoms compared to those who received placebo, with the effect persisting for at least 12 weeks following a single dose in the studied protocol. Response rates, meaning the proportion of participants who showed meaningful improvement, were substantially higher in the treatment group.
Why This Is Notable
Researchers and clinicians have pointed out that anxiety medication has seen relatively few new mechanisms of action over the past decade, with most standard options still relying on SSRIs, SNRIs, or benzodiazepines. MM120 represents a different approach, using a psychedelic-derived compound administered in a controlled clinical setting, an area of psychiatric research that has expanded significantly in recent years for conditions including depression and PTSD.
What This Research Does Not Prove
Phase 2b results are not the final step in drug development. Larger Phase 3 trials are typically required before a medication can be submitted for regulatory approval, and long-term safety data beyond the trial period is still limited. MM120 is not currently approved for treating anxiety and is not available for clinical use outside of research settings. Psychedelic-derived treatments generally require careful clinical supervision and structured administration protocols, unlike take-home medications.
Which Professional to See
Generalized anxiety disorder and other anxiety conditions are typically diagnosed and treated by a primary care physician, psychiatrist, or psychologist. Currently approved treatments, including certain antidepressants and structured therapies such as cognitive behavioral therapy, remain the standard first-line options.
Questions to Ask
Useful questions for a clinician include: What treatment options, including therapy and medication, are currently approved and appropriate for my anxiety symptoms? How long does it typically take to see improvement with current treatments? Are there clinical trials in my area studying newer anxiety treatments that I might be eligible to join?
Bottom Line
Early Phase 2b results for MM120 suggest a potential new approach to treating anxiety with effects lasting well beyond the dosing period, but the medication remains under investigation and is years away, at minimum, from potential approval and everyday clinical use. People currently experiencing anxiety symptoms should continue working with a clinician using established, approved treatments.
Related Topics
Related reading: Anxiety Disorders
This article is for informational purposes only and does not constitute medical advice. If you or someone you know is experiencing a mental health crisis, please contact a licensed healthcare provider or local emergency services.